Dr Daniel Tillett, Chief Scientific Officer and Executive Director has advised that; “I chose to exercise my 4.25 million 9.9c options early for tax planning purposes. I have not sold any Race shares to fund the conversion, nor do I intend to sell any shares in the immediate or medium- term future. I believe Race Oncology has an extraordinary opportunity with Bisantrene and I look forward to seeing our clinical trial plans progress
Waking up to the greatest news.
Ann: Appendix 3Y - Dr Daniel Tillett, page-2
-
- There are more pages in this discussion • 113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |